01
02
Bredin Prat is advising Sanofi in its discussions with the French State in connection with its proposed sale of its Opella consumer healthcare business to Clayton Dubilier & Rice (CD&R), a US private equity firm.
A tripartite agreement has been signed among Sanofi, CD&R and the State, setting forthcertain commitments made by Sanofi and CD&R concerning the future of Opella.
Completion of the transaction is scheduled for the second quarter of 2025 at the earliest, subject to finalisation of the definitive agreements and completion of the applicable labor consultations and customary regulatory approvals.
Bredin Prat is advising Sanofi with a team composed of :